Neurological Tumors
Conditions
Interventions
Sponsors
Eligibility
Inclusion criteria
Inclusion criteria: 1. Age 14 years (no upper limit); 2. Pathologically confirmed for the first time as primary or metastatic central nervous system tumor (any category according to WHO 2021) through postoperative tissue or stereotactic biopsy; 3. The date of the initial pathological report is within =500 mg and paired cerebrospinal fluid 5 ml; 7. Having contact information for follow-up (smartphone of the patient or immediate family member/ permanent residence address), and committing to complete at least 24 months of regular follow-up; 8. Signing a written informed consent form.
Exclusion criteria
Exclusion criteria: 1. Non-tumorous space-occupying lesions (demyelinating diseases, vascular malformations, infectious foci, etc.); 2. Pregnancy, lactation, or women of childbearing age with positive serum ß-hCG within 48 hours before enrollment; 3. History or concurrent malignancy, except for the following situations: AJCC stage 0 or stage I solid tumors that have been cured for >=5 years (e.g., cervical carcinoma in situ, thyroid microcarcinoma); 4. Presence of other systemic diseases with an expected survival of <12 months 5. Inability to obtain or completely archive baseline imaging/pathological/molecular data; 6. Investigator's judgment that the patient has severe cognitive or psychiatric disorders that prevent cooperation with scale assessments and follow-up; 7. Refusal or inability to provide biological specimens; 8. Participation in other interventional clinical trials (drug/device) that conflict with follow-up time points.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 2-month overall survival rate;12-month progression-free survival rate; | — |
Secondary
| Measure | Time frame |
|---|---|
| Tumor recurrence;Postoperative complications;Neurological function;Quality of life; | — |
Countries
China
Contacts
The First Affiliated Hospital of Soochow University